Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHECK: Prophylactic HIPEC CO2 in Colorectal Cancer
NCT03914820Phase 3Unknown
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jun 2020
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mitomycin c in colorectal carcinoma (CRC) (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Local Recurrence Free Survival at 3 years. Status: unknown.
02
Drugs
mitomycin c
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT03914820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03914820.